ACTUARIAL MANAGER - CONSULTING - RE/INSURANCE - LIFE OR P&C - BERMUDA - 10% TAX - HR101 About this opportunity... as an Associate with the IFoA / SOA / CAS or equivalent 5+ years' relevant actuarial experience in consulting with either P&C or Life...
ACTUARIAL CONSULTANT - RE/INSURANCE - LIFE OR P&C - BERMUDA - 10% TAX - HR107 About this opportunity Our client... with the IFoA / SOA / CAS or equivalent institute 12-18+ months' relevant actuarial experience in consulting with either P&C...
? You will possess excellent leadership skills and substantial knowledge in actuarial consulting for the Non-Life / P&C (re)insurance... must have at least 10 years of actuarial experience FCAS / FIA designation In-depth experience/knowledge of the Non-Life / P&C (re...
Exciting opportunity for an ACAS/FCAS with 5+ years' Reinsurance pricing experience to lead reinsurance treaty pricing and support Bermuda-Based underwriting teams. Role involves risk management, business planning, regulatory and portfolio ...
Indian benchmark indices continue bullish streak, fueled by potential rate cut by US Federal Reserve, FPI inflows, and rally in banking and IT stocks. Nifty 50 ends week with 1.30% gain, hitting new all-time high. Mid- and small-cap stocks also show strong performance. Continue Reading »
According to data collected from the Bombay Stock Exchange (BSE) website, the Emcure Pharmaceuticals IPO issue was oversubscribed 67.86 times. Qualified institutional buyers (QIB), non-institutional investors (NII), and retail investors showed strong bids on the third day. Continue Reading »
Anand Rathi recommends 2 'emerging picks' for July 2024, focusing on CONCOR and ideaForge Technology with a time horizon of 30-90 days. Continue Reading »
Stock Market Today: Sun Pharma share price has risen almost 25% year to date. The news flow recently has remained around regulatory actions by the USFDA for Dadra nd Halol plant Should you Buy , Sell or Hold the stock? Continue Reading »
Bansal Wire IPO subscription status shows overwhelming response from investors, with 59.57 times subscription. QIBs, NIIs, and retail investors actively participated. Price band set at ₹243-256 per share. Analysts bullish on long-term prospects, expecting decent listing gains of over 25%. Continue Reading »
V-Mart acquired Limeroad in FY23 to push its omnichannel strategy, but has been cutting costs to reduce Limeroad’s losses of late..Limeroad’s Ebitda loss in FY24 stood at ₹71.6 crore and V-Mart expects the FY25 loss to be 40-50% of that. Continue Reading »